microRNA Biomarkers as Potential Diagnostic Markers for Cancer - Genomic Biomarkers for Pharmaceutical Development - page 120

[132] Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymph-
oblastic leukemia / high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA
2006;103:7024-9.
[133] Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, et al. MicroRNA expression signatures accurately discriminate
acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 2007;104:19971-6.
[134] Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, et al. Identiication of new microRNA
genes and aberrant microRNA proiles in childhood acute lymphoblastic leukemia. Leukemia 2009;23:313-22.
[135] Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of pancreatic ductal
adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009;2:807-13.
[136] Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma microRNAs with serum CA19-9 for early
detection of pancreatic cancer. Int J Cancer 2012;131:683-91.
[137] Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression proile as a biomarker in the
diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58:610-18.
[138] Ren Y, Gao J, Liu JQ, Wang XW, Gu JJ, Huang HJ, et al. Differential signature of fecal microRNAs in patients
with pancreatic cancer. Mol Med Report 2012;6:201-9.
[139] Reddy C, Chilla D, Boltax J. Lung cancer screening: a review of available data and current guidelines. Hosp
Pract (Minneap) 2011;39:107-12.
[140] Smith RA, Duffy SW, Tabar L. Breast cancer screening: the evolving evidence. Oncology (Williston Park)
2012;26:471-5, 479-81, 485-6.
[141] Burt RW. Colorectal cancer screening. Curr Opin Gastroenterol 2010;26:466-70.
[142] Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from
the national lung screening trial (NLST). J Med Screen 2011;18:109-11.
[143] Osada H, Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer
Sci 2011;102:9-17.
[144] Dziadziuszko R, Hirsch FR. Advances in genomic and proteomic studies of non-small-cell lung cancer: clini-
cal and translational research perspective. Clin Lung Cancer 2008;9:78-84.
[145] Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep
2008;41:615-25.
[146] Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for
non-small-cell lung cancer. Lab Invest 2011;91:579-87.
[147] Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Schefler M, et al. miRNAs in lung cancer-
studying complex ingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009;9:353.
[148] Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA
biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011;6:482-8.
[149] Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of bio-
markers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
[150] Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker
for lung cancer. Clin Lung Cancer 2009;10:42-6.
[151] Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, et al. Serum microRNA biomark-
ers for detection of non-small cell lung cancer. PLoS One 2012;7:e32307.
[152] Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression proiles of
whole blood in lung adenocarcinoma. PLoS One 2012;7:e46045.
[153] Wang T, Lv M, Shen S, Zhou S, Wang P, Chen Y, et al. Cell-Free microRNA expression proiles in malignant
effusion associated with patient survival in non-small cell lung cancer. PLoS One 2012;7:e43268.
[154] Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung can-
cer and predicts poor prognosis. J Cancer Res Clin Oncol 2012;138(12):2045-50.
[155] Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21
and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol 2012;29(5):3190-7.
[156] Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers
for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-86.
[157] Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary
pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374.
[158] Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase
activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011;5:281-91.